Phase II study of ifosfamide, etoposide, and oxaliplatin (IFETOx) chemotherapy for relapsed or refractory non-Hodgkin's lymphoma.
- Authors
- Kim, Seon-Kyeong; Song, Moo Kon; Chung, Joo Seop; Shin, Ho-Jin
- Issue Date
- Dec-2013
- Publisher
- SPRINGER JAPAN KK
- Keywords
- Etoposide; Ifosfamide; Non-hodgkin' s lymphoma; Oxaliplatin; Relapse
- Citation
- INTERNATIONAL JOURNAL OF HEMATOLOGY, v.98, no.5, pp.543 - 548
- Indexed
- SCIE
SCOPUS
- Journal Title
- INTERNATIONAL JOURNAL OF HEMATOLOGY
- Volume
- 98
- Number
- 5
- Start Page
- 543
- End Page
- 548
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/142694
- DOI
- 10.1007/s12185-013-1440-7
- ISSN
- 0925-5710
- Abstract
- As part of an effort to develop a more effective and safe treatment for relapsed or refractory non-Hodgkin’s lymphoma (NHL), we conducted a phase II study of the oxaliplatin, etoposide, and ifosfamide (IFETOx) regimen. Patients with relapsed or refractory NHL and a performance status of 0–2 were eligible. The IFETOx consisted of etoposide at 100 mg/m2 on days 1–3, oxaliplatin at 130 mg/m2 on day 2, and ifosfamide 5,000 mg/m2 on day 2, every 21 days. The primary endpoint was the overall response rate (ORR) for IFETOx regimen. A total of 23 eligible patients were enrolled. The median age was 58 years (range 19–76 years), and the male-to-female ratio was 15:8. The disease status was as follows: 15 patients had relapsed and 8 patients were refractory to treatment. The ORR for IFETOx chemotherapy was 65.2 %. In the 15 patients who responded to the protocol treatment, five underwent hematopoietic stem cell transplantation. The 2-year probability of progression-free survival and overall survival rates were 51.4 and 56.1 %, respectively. Grade 3/4 neutropenia was observed in 73.9 % of the patients. No significant renal impairment was observed. In conclusion, IFETOx chemotherapy shows a tolerable toxicity profile and efficacy as a salvage treatment regimen for relapsed or refractory NHL.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 교육협력지원교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/142694)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.